MedTrace Logo

Acute Exposure of Simulated Hypoxia on ECG and Non-invasive Blood Pressure

NCT03581851 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-01-07

No results posted yet for this study

Summary

Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FIO2: 15.1% = equivalent to 2500m above sea level) on ECG repolarizations and non-invasive blood pressure measurements by Finapres® NOVA Technology.

Conditions

  • Pulmonary Hypertension

Interventions

DEVICE

Simulated Altitude: (FiO2: 15.1)

Inhalation of deoxygenated air through an altitude simulator ("Altitrainer") for approximately 1 hour given by a facemask.

DEVICE

Shamed Hypoxia (FiO2: 20.9)

Inhalation of unmodified air through an altitude simulator ("Altitrainer") for approximately 1 hour given by a facemask.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Silvia Ulrich, MD · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2019-04-01
Completion
2019-04-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03581851 on ClinicalTrials.gov